Radioimaging: IV: 10 mCi (370 MBq).
There are no dosage adjustments provided in the manufacturer's labeling.
There are no dosage adjustments provided in the manufacturer's labeling.
Refer to adult dosing.
IV: Administer as a single IV bolus injection in a total volume of ≤10 mL. Following the injection, flush with NS. Initiate imaging ~80 minutes after injection. Refer to manufacturer's labeling for additional administration information.
Radiopharmaceutical; use appropriate precautions for handling and disposal. Waterproof gloves should be worn and effective shielding should be used during handling and administration.
Radioimaging: For use with positron emission tomography (PET) imaging of the brain to estimate the density and distribution of aggregated tau neurofibrillary tangles (NFTs) in adult patients with cognitive impairment who are being evaluated for Alzheimer disease.
Limitations of use: Not indicated for use in the evaluation of patients for chronic traumatic encephalopathy (CTE).
Flortaucipir F18 may be confused with Florbetaben F18, Florbetapir F18, Fluciclovine F 18, Fludeoxyglucose F 18, Fluoroestradiol F18, and Flutemetamol F18.
Radiopharmaceutical: Use appropriate precaution for handling, disposal, and minimizing exposure to patients and health care personnel. Use under supervision of experienced personnel. Should be stored in original lead container or adequate radiation shield.
The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.
1% to 10%:
Local: Pain at injection site (1%)
Nervous system: Headache (1%)
<1%: Cardiovascular: Increased blood pressure
There are no contraindications listed in the manufacturer's labeling.
Disease-related concerns:
• Malignancy: Patients are exposed to some radiation during treatment; large cumulative amounts of radiation exposure may increase the risk of cancer.
Special handling:
• Radiopharmaceutical: Use appropriate precautions for handling, disposal, and minimizing exposure to patients and health care personnel. Use only under supervision of individuals with experience/training in the handling of radioactive materials approved by the applicable regulatory authority.
Other warnings/precautions:
• Experienced staff: Images should only be interpreted by specially trained personnel.
• Limitations: Only uptake of tracer in neocortex should be used to interpret a positive scan. Small foci of noncontiguous tracer uptake may lead to a false-positive scan. Interpret scans that have isolated or noncontiguous, small foci in any region with caution. In patients with a negative scan, consider additional evaluation; neurofibrillary tangles may still be present at levels that qualify for diagnosis of Alzheimer disease. The ability to detect tau pathology may be lower in patients with earlier stages of disease. Imaging does not target β-amyloid.
None known.
There are no known significant interactions.
Evaluate pregnancy status prior to use in females of reproductive potential.
All radiopharmaceuticals have the potential to cause fetal harm if exposure occurs during pregnancy.
It is not known if flortaucipir F18 is present in breast milk.
Breastfeeding is not recommended by the manufacturer for 4 hours after administration to minimize potential exposure to a breastfed infant.
Evaluate pregnancy status prior to use in females of reproductive potential.
Flortaucipir F18 binds to aggregated tau protein; the F18 isotope produces a positron signal that is detected by a positron emission tomography scanner.
Distribution: <10% of F18 radioactivity present in blood 5 minutes post administration; <5% of F18 radioactivity present in blood 10 minutes post administration.
Excretion: Hepatobiliary and renal.
